News

Our Research Studies

10 Sep 2018

It is our primary aim to fund the most promising new childhood cancer research ideas in the North West. As a result of our funding researchers are able to obtain preliminary results to back up their ideas, which they can then use to secure large-scale funding from the big cancer research charities and pharmaceutical companies.

Each year, we ask medical and scientific institutions to apply to us for grants to fund their research ideas. These  applications are then verified by our independent Scientific Advisory Board, who make recommendations as to which projects are most promising and should receive our funding. We typically fund one to two years of initial research.

The average cost of a research project is £60,000 for one year.

Whilst our research is conducted in the North West of England, our beneficiaries are children with cancer all over the world. The research projects that we help to get off the ground can lead to critical breakthroughs in our global understanding of childhood cancer and a step change in the way children with cancer are diagnosed and treated.

Research projects that we started have gone on to be funded by the likes of Cancer Research UK and the Department for Health, and have led to international research partnerships between the UK, Canada and the US.

£2.5 million over 25 years

Since Friends of Rosie was formed in 1991, we have funded 25 research projects in the North West of England. This research has focused on different ways in which to improve the treatment and outlook for children with cancer.

In financial terms, that’s around £2.5 million worth of funding, raised and donated by our amazing supporters.

Here’s the full list of projects that we have proudly funded:

To identify and isolate genes important in the initiation and progression of childhood solid tumours with a focus on Wilms tumour – kidney cancer in children.
Dr Paul Hoban & Dr Anna Kelsey (1993)
The use of radiation activated gene therapy as a novel method of cancer treatment*.
Dr B Marples, Paterson Institute Manchester, London, Toronto, USA. (1996)
*This research went on to attract long term funding at Mount Vernon Hospital, Middlesex (2001)
The way in which cells from cancers of the nervous system (neuroblastoma) manage to evade being killed by cytotoxic drugs
Prof Tim Eden, Prof John Hickman and Dr Christine Cresta, University of Manchester (1996)
Risk factors for the development of the child and family in the nine months following the diagnosis of childhood cancer
Prof Hill (Alder Hay Children’s Hospital), Dr Mackie and Prof Eden (RMCH) (1997)
Protection of bone marrow cells against the damaging effects of cytotoxic drugs, using gene therapy.
Dr J Rafferty, Paterson Institute. (1998)
A comparison of the frequency of unusual inherited mutations in the families of children with cancer as compared with their frequency in control families.*
Dr M Taylor, St Mary’s Hospital.  (1998)
*Dr M Taylor received a grant from the Department of Health to extend his work on unusual mutations in children with cancer (2003)
A study of the timing of drug administration, with the aim of preventing damage to normal cells, while still killing cancer cells.
Dr H Robson, Christie Hospital. (1998)
An investigation of whether damage to a particular gene, called MLL, is associated with the occurrence of rare cases of leukaemia caused by the treatment of a previous cancer.
Dr A Ng, Christie Hospital. (1999)
A long term comparison of the possible damaging effects on the density of bone in children, cured of cancer, which has been treated by different methods.
Dr B Brennan, Manchester University and Royal Manchester Children’s Hospital. (1999)
Using data from the Manchester Children’s Tumour Registry to determine the relative importance of genetic and environmental factors in the causation of lymph gland cancer in children.
Professor J Birch, Royal Manchester Children’s Hospital. (1999)
A study of multiple gene therapy to protect bone marrow cells from the potential damaging effect on normal cells of cancer treatment that uses more than one drug.* 
Dr L Fairbairn, Paterson Institute. (1999)
*Dr L Fairburn secured further funding with a view to clinical trials of bone marrow protection in the future. (2001)
Establishment of a research database for kidney cancers in children.
Dr R McNally, Royal Manchester Children’s Hospital. (2001)
An investigation of the mechanism by which the drug asparaginase exerts its effect, with the aim of enabling this important drug to be used more effectively in the treatment of children with cancer.
Dr E J Estlin, Royal Manchester Children’s Hospital and Salford University. (2002)
A comparison of the early stages in the development of the blood cells of children with Down’s Syndrome and those of control children, in order to understand why some children with Down’s Syndrome develop leukaemia.
Dr R Wynn, Royal Manchester Children’s Hospital. (2004)
The effects of hypoxia on drug-induced Apoptosis in neuroblastoma.
Dr Makin – University of Manchester (2006)
Study of biochemical changes which occur within single cells.
Prof M White – University of Liverpool (2006 )
Gene activity in childhood brain tumours.
Dr Stephen Meyer – University of Manchester (2008)
Studies on an inherited cancer susceptibility.
Prof A Whetton – University of Manchester (2010)
Hypoxia-induced drug resistance in Osteocarcoma.
Dr J Adamski and Dr G Makin, University of Manchester (2011)
How changes in the genetic code of medulloblastoma cells result in tumour growth and treatment resistance.
Dr Martin McCabe, University of Manchester (2012)
The consequences of childhood brain tumours and their treatment with cranial radiotherapy.
Dr Estlin (RMCH) & Prof Daniela Montaldi, University of Manchester (2012)
Investigating the feasibility of tumour infiltrating lymphocyte therapy for paediatric malignancies with high risk and poor prognosis.
Dr Gray Kueberuwa, University of Manchester (2017 & 2018)
Researching the treatment and improved detection of osteosarcoma.
Dr Katherine Finegan, University of Manchester (2017 & 2018)